JP2010530889A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530889A5
JP2010530889A5 JP2010513433A JP2010513433A JP2010530889A5 JP 2010530889 A5 JP2010530889 A5 JP 2010530889A5 JP 2010513433 A JP2010513433 A JP 2010513433A JP 2010513433 A JP2010513433 A JP 2010513433A JP 2010530889 A5 JP2010530889 A5 JP 2010530889A5
Authority
JP
Japan
Prior art keywords
compressed tablet
lubricant
raltegravir
total weight
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010513433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530889A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/067624 external-priority patent/WO2009002823A2/en
Publication of JP2010530889A publication Critical patent/JP2010530889A/ja
Publication of JP2010530889A5 publication Critical patent/JP2010530889A5/ja
Withdrawn legal-status Critical Current

Links

JP2010513433A 2007-06-22 2008-06-20 アタザナビルを含む錠剤組成物 Withdrawn JP2010530889A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94570607P 2007-06-22 2007-06-22
PCT/US2008/067624 WO2009002823A2 (en) 2007-06-22 2008-06-20 Tableted compositions containing atazanavir

Publications (2)

Publication Number Publication Date
JP2010530889A JP2010530889A (ja) 2010-09-16
JP2010530889A5 true JP2010530889A5 (enExample) 2011-07-21

Family

ID=39645408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010513433A Withdrawn JP2010530889A (ja) 2007-06-22 2008-06-20 アタザナビルを含む錠剤組成物

Country Status (11)

Country Link
US (1) US20100178339A1 (enExample)
EP (1) EP2178511B1 (enExample)
JP (1) JP2010530889A (enExample)
KR (1) KR20100033378A (enExample)
CN (1) CN101801348A (enExample)
AT (1) ATE499927T1 (enExample)
AU (1) AU2008268627A1 (enExample)
DE (1) DE602008005316D1 (enExample)
ES (1) ES2360336T3 (enExample)
MX (1) MX2009013462A (enExample)
WO (1) WO2009002823A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2178512B1 (en) * 2007-06-22 2011-03-09 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
EP3970702A1 (en) 2009-10-26 2022-03-23 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
US20130203759A1 (en) * 2010-04-09 2013-08-08 Faranak Nikfar ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
CA2849546A1 (en) 2010-09-28 2012-04-05 Ratiopharm Gmbh Dry processing of atazanavir
WO2012114352A2 (en) * 2011-02-21 2012-08-30 Hetero Research Foundation Pharmaceutical compositions of maraviroc and process for the preparation thereof
CA2833006A1 (en) * 2011-04-22 2012-10-26 Merck Sharp & Dohme Corp. Taste-masked formulations of raltegravir
US20140038992A1 (en) * 2011-04-25 2014-02-06 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
US9968607B2 (en) * 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
PT3054926T (pt) * 2013-10-07 2018-10-26 Bristol Myers Squibb Holdings Ireland Formulação de atazanavir e cobicistat para tratamento de hiv
KR101497508B1 (ko) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CN105237526B (zh) * 2014-06-20 2018-01-23 朱靖华 一种抗艾滋病毒药物及其制备方法
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940998A (en) * 1953-10-15 1960-06-14 Ajinomoto Kk Process for resolution of racemic glutamic acid and salts thereof
GB919491A (en) * 1958-12-23 1963-02-27 Ici Ltd Pharmaceutical compositions
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US3980637A (en) * 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
US4556654A (en) * 1983-06-28 1985-12-03 Warner-Lambert Company Antimicrobial substituted anthra[1,9-cd]pyrazol-6(2H)-ones
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5753652A (en) * 1991-07-03 1998-05-19 Novartis Corporation Antiretroviral hydrazine derivatives
CA2103932A1 (en) * 1992-11-05 1994-05-06 Ramesh N. Patel Stereoselective reduction of ketones
US5461067A (en) * 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
JP3529904B2 (ja) * 1995-06-19 2004-05-24 鐘淵化学工業株式会社 光学活性１−ハロ−３−アミノ−４−フェニル−２−ブタノール誘導体の製造法
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5767316A (en) * 1995-11-17 1998-06-16 Ajinomoto Co., Inc. Process for producing 3-amino-2-oxo-1-halogenopropane derivatives
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6737264B1 (en) * 1999-01-21 2004-05-18 Kaneka Corporation Method for purifying and isolating (2s,3s)- or (2r,3s)-halohydrin derivatives
EP1067125B1 (en) * 1999-01-29 2006-07-26 Kaneka Corporation PROCESSES FOR THE PREPARATION OF threo-1,2-EPOXY-3-AMINO-4-PHENYLBUTANE DERIVATIVES
JP2002540102A (ja) * 1999-03-22 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ｃＧＭＰホスホジエステラーゼの縮合ピリドピリダジン阻害剤
US6605732B1 (en) * 1999-05-03 2003-08-12 Aerojet Fine Chemicals Llc Clean, high-yield preparation of S,S and R,S amino acid isosteres
KR100708221B1 (ko) * 1999-08-31 2007-04-17 아지노모토 가부시키가이샤 에폭사이드 결정의 제조방법
US6399393B1 (en) * 1999-09-21 2002-06-04 The United States Of America As Represented By The Department Of Energy Cryogenic homogenization and sampling of heterogeneous multi-phase feedstock
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CZ20011726A3 (cs) * 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
WO2002014528A1 (en) * 2000-08-16 2002-02-21 Bristol-Myers Squibb Company Stereoselective reduction of substituted oxo-butanes
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
KR20020046948A (ko) * 2000-12-12 2002-06-21 에가시라 구니오 에폭사이드 결정의 제조방법
HRP20040181A2 (en) * 2001-08-31 2004-08-31 Bristol Myers Squibb Co Use of atazanavir in hiv therapy
KR100933625B1 (ko) * 2001-09-04 2009-12-24 다우 글로벌 테크놀로지스 인크. 수성 에어 포움, 이를 사용한 고체 입자의 응집방법 및 피복방법
CA2463976C (en) * 2001-10-26 2007-02-13 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US7384734B2 (en) * 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
US20050148523A1 (en) * 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
US7582468B2 (en) * 2005-05-25 2009-09-01 Bristol-Myers Squibb Company Process for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof
US20070059360A1 (en) * 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2010530889A5 (enExample)
JP2010530892A5 (enExample)
HRP20110294T1 (hr) Smjese u obliku tablete koje sadržavaju atazanavir
UY27995A1 (es) Nuevas formulaciones farmacéuricas solidas que comprenden telmartisano y su preparación
EA023807B1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
JP2012197280A5 (enExample)
NZ605469A (en) Nalbuphine-based formulations and uses thereof
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
HRP20250604T1 (hr) Formulacije tableta neratinib maleata
FI3265084T3 (fi) Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
WO2008067127A3 (en) Water insoluble polymer matrix for drug delivery
HRP20140146T1 (hr) Smjese koje sadrže atazanavir oblikovane u tablete
JP2017525712A5 (enExample)
JP2010530890A5 (enExample)
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
HRP20161262T1 (hr) Tablete ulipristal acetata
SI2729130T1 (en) Combined formulations of darunavir
JP2011525501A5 (enExample)
WO2008048469A3 (en) Controlled-release coated dosage forms containing galantamine
WO2010020856A3 (en) Rate modulated delivery of drugs from a composite delivery system
RU2014115287A (ru) Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения
WO2010005732A2 (en) Composition and method of preparation of release systems for constant (zero-order) release of active agents
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
HRP20151347T1 (hr) Nova kombinacija
HRP20130123T1 (hr) Postupak lijeäśenja bolesti